Less than a month after locking down a lease for a new U.S. headquarters, radiotherapy outfit AdvanCell is poised to push its ...

Johnson & Johnson has stopped development of an eye disease gene therapy after reviewing data from one of its key readouts for 2026. Exiting the first quarter, J&J named (PDF) data from the phase 2b ...

Johnson & Johnson’s MedTech business posted operational sales growth of 3.6% in the second quarter, reaching $8.93 billion, ...

Medtronic issued a voluntary recall of 102 lots of its Harmony delivery catheter system due to a risk of the their tips detaching, which could result in serious injury or death. The recall, which was ...

Attovia Therapeutics has filed for an IPO to secure funding for assets including a pote | Attovia Therapeutics has filed for ...

Summit Therapeutics has cleared out an asset from its pre-ivonescimab history, offloading the antibiotic candidate ridinilazole to the OpenAI-backed startup Biossil for $500,000 upfront. Summit sought ...

Biogen's leading tau-targeting candidate has slowed cognitive decline across a suite of different clinical assessments, ...

Spero Therapeutics is pivoting from antibiotics to immune and inflammation indications by licensing a CD40L antibody from ...

Biogen leaders took to an investor call today to defend the phase 2 readout of the company’s anti-tau Alzheimer’s disease ...

Chai Discovery has continued its whirlwind emergence, closing its third financing round in less than a year to bring its ...

Avere Therapeutics has burst onto the scene by securing a public listing via a reverse merger with NextCure, while stocking ...

Around 59% of clinical trial sites are seeing fewer eligible patients recruited due to inefficiencies with their recruitment ...